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1Introduction
Demand in the United States for dietary supplements and herbal products has exploded in past years. One
report states that demand for dietary supplements has increased almost 50 percent since 1995.1 Congress,
therefore, in response to the increased demand and other motivations (to be discussed below), has passed
legislation intended to increase the amount and quality of information available to consumers in an eort to
maximize the benets of such products. Congress has attempted to develop a regulatory scheme in which an
atmosphere of cooperation exists between the government, the dietary supplement industry and consumers
of these products. However, it seems that Congress' intent in passing the Dietary Supplement Heath and
Education Act (and related legislation) has not come to fruition.
The Food and Drug Administration's Regulatory Powers
One of the missions of the FDA is to protect consumers from adulterated products (food, drugs and cosmet-
ics) Regardless of the changes introduced since the enactment of the Federal Food, Drug and Cosmetic Act
(FDCA) of 1938 and subsequent, related legislation, this mission of the FDA remains the same. The FDA
is a descendent of early regulators who prosecuted charlatans who marketed questionable products, making
wild claims about the medicinal qualities of potions and compounds during the nineteenth century. Pursuant
1Linda Ciampa, FDA Requires New Diet Supplement Labels, http://www.cnn.com/HEALTH/9903/23/dietary.supplements/hsindex.html,
(3/23/00).
2to this mission, the Secretary of Health and Human Services has the authority to promulgate regulations
to enforce federal laws, including the Federal Food, Drug and Cosmetic Act of 1938. In promulgating the
enforcement regulations, the Secretary follows statutory procedures which require publication of the Secre-
tary's proposal. Interested persons are invited to respond, and those who would be adversely eected may
submit objections. If material issues are raised during this process, a hearing may be held. The powers given
to the Secretary under the Federal Food Drug and Cosmetic Act have been delegated to the Commissioner
of Food and Drugs. A statutory provision is available for review of orders granted for the establishment or
amendment of such regulations. In reviewing promulgating regulations, courts will seek a rational basis for
such regulations in consideration of pertinent circumstances and will consider whether the regulation falls
within the powers delegated to the FDA.2
The FDA is recognized by Congress as having the following powers in regulating dietary supplements:

Refer for criminal action any company that sells a dietary supplement that is toxic or unsanitary [Section 402 (a)]

Obtain an injunction against the sale of a dietary supplement that has false or unsubstantiated claims fSection 403(a),(r6)g

Seize dietary supplements that pose a \unreasonable or signicant risk of illness or injury" [Section 402(f)]

Sue any company that makes a claim that a product cures or treats a disease [Section 201(g)]

2Drugs and Controlled Substances, 25 Am. Jur. 2d x90 (1996).
3Stop a new dietary ingredient from being marketed if FDA does not receive enough safety data in advance [Section 413]

Stop the sale of an entire class of dietary supplements if they pose an imminent public health hazard [Section 402(f)]

Require dietary supplements to meet strict manufacturing requirements (Good Manufacturing Practices), including potency, cleanliness and stability [Section 402(g)3
History
FDA control and regulation of dietary supplements has an extensive history. The history tells a story of a
tug-of-war existing between Congress and the FDA, during which the FDA has taken an aggressive stance on
regulating dietary supplements and Congress ultimately has responded by severely limiting the FDA's power
through legislative eorts. Methods employed by the FDA to regulate and control dietary supplements have
included \classication methods, eectiveness provisions, and labeling requirements."4
The Pure Food and Drug Act of 1906 was an early congressional eort aimed at controlling the quality of
foods and drugs which reached the public. The FDC did little in addressing the need for pre-screening of
drugs, an issue later addressed in the Federal Food, Drug, and Cosmetic Act of 1938. This Act established
a classication system for foods and drugs containing vitamins, which was dependent on the marketing and
labeling of the products. In a nutshell, products intended to treat, mitigate or cure disease were considered
drugs and those products (except for conventional foods) aecting the structure or function of the body were
also considered drugs.
4Kelly Ann Kaczka, From Herbal Prozac to Mark McGuire's Tonic: How the Dietary Supplement Health and Education Act
Changed the Regulatory Landscape for Health Products, 16 J. Contemp. Health L. & Pol'y 463, 478 (2000).
4Labeling requirements were established in the FDCA, as well. Dietary Supplements were not addressed by
the Act. However, relevant to our topic, the Act did confer power to the FDA to \regulate and declare
misbranded dietary foods."5 The Act gave the Secretary of Health and Human Services the authority to
determine and regulate appropriate labeling requirements for foods claiming special dietary uses.6 It gave
the FDA the power to establish the criteria for evaluating nutritional information reaching the public. The
FDA, however, failed to fully answer questions regarding the labeling and regulation of some products when
establishing its regulations surrounding this issue. Rather than establishing regulations to the extent of its
discretionary powers, the FDA chose to regulate labeling guidelines through litigation.7
Litigation-based regulation of labeling claims proved inecient, leading to FDA proposals for regulations
in 1962. These regulations gave the FDA tight control over labeling claims made by manufacturers and
required manufacturers to demonstrate the eectiveness of new drugs before they hit the market. As di-
etary supplements could be considered either drugs or food, depending on how the manufacturer marketed
them. As a result, the new regulations gave the FDA authority to tightly regulate the labeling of dietary
supplements.
The FDA, in general, had judicial support in its eorts to regulate dietary supplements with drug standards.
As a result of the increasing market for herbs and vitamin supplements, FDA eorts to regulate the market
has increased. In response, manufactures have supported legislation which narrows the FDA's expanding
regulatory eorts. The Proxmire Vitamin Mineral Amendment of 1976 expressly forbid the FDA to regulate
5Id. at 468.
621 U.S.C. x403 (1998).
7Kaczka, supra note 4, at 471.
5potency limits or classifying a vitamin or mineral as a drug based on its potency or to limit the marketing
of multivitamins. As an initial attempt to rein in the FDA's stance on dietary supplements, the amendment
had little eect on the FDA's assertive eorts to regulate supplements.
The passage of the Nutritional Labeling and Education Act of 1990 (NLEA) oered the FDA additional
control over dietary supplements. It was intended to overhaul all food labeling, including the labels on
dietary supplements. The Act established a nutritional labeling requirement for foods and supplements. The
NLEA established that health claims made for food products were subject to the standard of \signicant
scientic agreement." Congress chose to establish the standard for dietary supplements on a separate section
of the Act. The Act established that claims made on the labels of dietary supplements are \subject to a
procedure and standard, respecting the validity of such a claim, established by regulation of the Secretary
[of Health and Human Services]."8
The Act opened the door to the FDA establishing procedural regulations for health claims on both food
and dietary supplements. Regardless of Congress' intent in providing a separate provision for labeling
regulations for supplements, the enormous discretion oered to the FDA by the ambiguous requirement
allowed the FDA to implement its own interpretation of the Act's labeling requirements: \[T]he FDA took
that separate requirement for supplements to mean that, if it wanted, it could apply to supplements the
same `signicant scientic agreement' standard the law applied to food."9 However, Congress' reaction to
this move was swift.
The FDA's machinations and public pressure combined to produced additional congressional legislation:
the Dietary Supplement Act of 1992 (DSA). This Act slowed FDA's eorts to implement the regulation
promulgation process regarding health claims and labeling in the NLEA by placing a one-year delay on
its implementation. Regardless of the powers oered to the FDA by the passage of the NLEA, the DSA
821 U.S.C. x 343 (r) (5) (D)
9Eric F. Greenberg, Dietary Supplements Caught in Murky Regulatory Scheme, Chicago Daily Law Bulletin, vol. 144, no. 250
(December 23, 1998).
6was an immediate eort to limit those powers. Congress ordered the FDA to review its stance on dietary
supplements, but to no avail. When the one-year waiting period had passed, the FDA persisted in using the
same \signicant scientic agreement" standard that applied to foods.
Despite Congress' eorts to limit the FDA's regulatory actions, the FDA continued its assertive eorts in
response to increasingly reported health-related problems attributed to the use of dietary supplements. As
the FDA's eorts were increasing, Congress responded with the passage of the Dietary Supplement Health
and Education Act of 1994, which created new limits on the FDA's eorts to regulate dietary supplements.
The Dietary Supplement Health and Education Act of 1994
Against the backdrop of the antagonistic relationship between the FDA and the dietary supplement industry,
and in an eort to reduce the ambiguity and conicts about the labeling of dietary supplements, the DSHEA
amended the Federal Food, Drug and Cosmetic Act. It set forth a federal denition for \dietary supplements,"
a broader meaning than the FDA employed, allowing for dietary supplements to generally be considered food.
:
Congress dened \dietary supplement" to mean products that are intended to supplement the diet
that contain one or more of certain dietary ingredients, such as:

A vitamin or mineral,

An herb or other botanical,

7An amino acid,

A dietary substance r use by man to supplement the diet by increasing the total dietary intake, or

A concentrate, metabolite, constituent, extract, or

Combination of the preceding ingredients,
And, that meets other criteria specic in Section 201 (FF) (2)-(3).10
The Act also set forth a regulatory framework for dietary supplements. As noted above, the passage of
the DSHEA was a response to the FDA's continued, aggressive approach to regulating dietary supplements.
Congress was also motivated by e need promote good nutrition and health through the increase of information
on dietary supplements available to the public (perhaps in reaction to President Clinton's eorts for health
care reform). Through the DSHEA, Congress sought to restructure the FDA's authority in regulating dietary
supplements, a deregulation of the dietary supplement market, so to speak. The DSHEA has three main
components: \research, labeling, and standard of proof for safety."11
As previously noted, the NLEA was interpreted by the FDA as requiring \signicant scientic agreement"
regarding labeling claims. The DSHEA requires the substantiation requirements for claims, but actually
fails to dene \the nature or scope of the requisite substantiation."12 The Federal Trade Commission has
sought to articulate the required standards for substantiation. It considers human and animal studies, in
vitro data and traditional use information. These types of evidence may well be adopted by the FDA when
11Kaczka, supra note 4, at 485.
12I. Scott Bass & Charles J. Raubicheck, Marketing Dietary Supplements (2000) at IV-7.
8it sets forth its requirements.13
Before the enactment of the DSHEA, the standard of proof regarding the safety of dietary supplements was
adjudicated under the Federal Food, Drug and Cosmetic Act. If a dietary supplement was deemed unsafe
under the Act, the Act imposed a burden on the manufacturer to \show that its ingredient was covered by a
food additive regulation, or that the ingredient was not a food additive but instead was generally recognized
as safe."14 In addition to requiring rulemaking which denes adulterated supplement as posing a substantial
and unreasonable risk and banning supplements which pose an imminent threat, the Act shifted the burden
of proof concerning dietary supplement safety to the FDA rather than the manufacturer: "Manufacturers
are responsible for providing information to support their claims and need not prove safety or eectiveness.
Instead, under the DSHEA the FDA bears the burden of proving the products are unsafe."15
The DSHEA also allows manufacturers to make certain kinds of statement on the label of dietary supple-
ments, statements which do not need pre-approval from the FDA: \Those claims essentially allow a company
to tell how a substance benecially aects the way the body functions, how you maintain or support your
immune system or the mechanism by how that dietary ingredient operates in your body. They can also take
about general well-being claims."16 The Act allows for statements addressing the eect of dietary supple-
ments on the structure or function of the body. It does not, however, allow manufacturers to make so-called
\disease claims", statements which claim that a supplement treats or prevents disease: \...Congress has
permitted dietary supplements to be intended to aect the structure or function of the body, but it has not
permitted dietary supplements to be intended to treat, prevent, mitigate, cure, or diagnose disease, except
that dietary supplements may bear authorized health claims."17 The Act denes acceptable statements in
13Id.
14I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act (1996) at 44.
15Kaczka, supra note 4, at 488.
16Dietary Supplement Health and Education Act: Is the FDA Trying to Change the Intent of Congress? supra note 3, at 83.
17Id. at 45.
9the following manner:
...[A] statement for a dietary supplement may be made if {
(A)
the statement claims a benet related to a classical nutrient deciency disease and discloses the prevalence of such disease in the United States, describes the role of a nutrient or dietary ingredient intended to aect the structure or function in humans, characterizes the documented mechanism by which a nutriment or dietary ingredient acts to maintain such structure or function or describes general well-being from consumption of a nutrient or dietary ingredient,
(B)
the manufacturer of the dietary statement has substantiation that such statement is truthful and not misleading18...
Manufacturers are required to notify the FDA of statements made on labels within 30 days of marketing.
As noted, the claims must be substantiated. Structure/function claims must also be accompanied by a
disclaimer stating the following: This statement has not been evaluated by the FDA. This product is not
intended to diagnose, treat, cure, or prevent any disease."
Although published after the passage of the DSHEA, the intent of Congress in passing the DSHEA is as
follows:
DSHEA amended the Federal Food, Drug and Cosmetic Act (FD&C Act) to dene the
term \dietary supplement" and establish a regulatory framework for dietary supplements.
In doing so, Congress made 15 signicant ndings that emphasize the importance of diet
and nutrition, including dietary supplement use, in promoting health and reducing the risk
of disease. FDA acknowledges these ndings. DSHEA provides for broad access to dietary
supplements for consumers and also recognized that there is a need for a rational regulatory
framework that provides FDA authority to remove from the market products that pose a
\signicant or unreasonable" risk to consumers or that are otherwise adulterated and to
require that labeling for dietary supplements be accurate.19
Congressional intent in deregulating the dietary supplement industry comes through loud and clear in the
new labeling requirements. A manufacture simply must send a letter to the FDA when introducing a new
product with a health claim and for new uses or a change in dosage recommendation. The FDA need not
approve products or claims, oering essentially an un-checked ability for manufacturers to make claims and
10allowing them to eliminate negative information required in the labels of over-the-counter (OTC) drugs.
Regardless of the congressional intent implied in the new Act, \what Congress intended as a new safe harbor
for dietary-supplement claims has been something of a mineeld, thanks largely to an unfriendly attitude
on the part of the [FDA]."20
Implementation of the DSHEA
The FDA's role in instituting the DSHEA is in the promulgation of regulations which could implement
the Act. Rules promulgated to date include establishing a \Supplement Facts" requirement on dietary
supplement labels (similar to the nutritional labeling on foods) and proposing rules for establishing \Good
Manufacturing Practices" for manufacturers.
In April of 1998, the FDA published its proposed rule identifying the types of structure/function statements
which could be made on a dietary supplement label under the DSHEA: \[The] proposed rule den[ed] the
types of statements that can be made concerning the eect of a dietary supplement on the structure or
function of the body."21 This presented the FDA with the need to distinguish between structure/function
claims and disease claims, which it had heretofore not addressed. The rule-making was intended to imple-
ment the portion of the DSHEA, as noted above, which allowed manufacturers to make structure/function
claims and provide direction to the supplement industry with the types of statements which they could make
20Greenberg, supra note 9.
21Dietary Supplement Health and Education Act: Id the FDA Trying to Change the Intent of Congress?, supra note 3 at 39.
11regarding the eects of supplements on the structure or function of the body. The FDA was attempting
to provide this guidance and respond to information provided by the Commission on Dietary Supplement
Labels (established by the DSHEA). The proposed rule attempted to clarify the types of statements which
manufactures may make by distinguishing between permissible statements referring to the role of the dietary
supplement in aecting the structure and function of the body and those which are impermissible disease
claim statements. In developing the proposed rule, the FDA considered the following guidelines given by the
Commission of Dietary Labeling to assist in dierentiating structure/function claims and disease claims:

While the Commission [on Dietary Supplement Labels) recognizes that the content of a claim has to be considered on a case-by-case basis, the Commission proposes the following guidelines:
1)
Statements of nutritional support should provide useful information to consumers about the intended use of the product.
2)
Statements of nutritional support should be supported by scientically valid evidence substantiating that that the statements are truthful and not misleading.
3)
Statements indicating the role of a nutrient or dietary ingredient in aecting the structure or function of humans may be made when the statements do not suggest disease prevention or treatment.
4)
Statements that mention a body system organ, or system aected by the supplement using terms such as \stimulate," \maintain," \support," \regulate," or \promote" can be appropriate when the statements do not suggest disease prevention or treatment or use for a serious health condition that is beyond the ability of the consumer to evaluate
5)
Statements should not be made that the products \restore" normal or \correct" abnormal function when the abnormality implies the presence of disease. An example might be a claim to \restore" normal blood pressure when the abnormality implies hypertension.
6)
12Health claims are specically dened under the NLEA as statements that characterize the relationship between a nutrient or food component and a specic disease or health-related condition. Statements of nutritional support should be distinguished from the NLEA health claim in that they do not state or imply a link between a supplement and prevention of a specic disease or health-related condition.
7)
Statements of nutritional support are not to be drug claims. They should not be drug claims. They should not refer to specic diseases, disorders, or classes of disease and should not use drug-related terms such as \diagnose," \treat," \prevent," \cure," or \mitigate."22
In presenting this rule, the FDA employs these guidelines to clarify permitted structure/function claims,
denes disease, and establishes the criteria for identifying disease claims.23
The FDA recognizes in its proposed rule that the DSHEA allows \the manufacturer of a dietary supplement
[to] make a truthful nonmisleading labeling statement claiming that the product aects the structure or
function of the body, unless the statement expressly or implicitly claims an eect on a disease...."24 The
proposed rule denes permitted structure/function claims in the following manner:
Under proposed x 101.93(f), dietary supplement labels and labeling may bear structure/function
statements that are not disease claims within the meaning of proposed x 101.93(g) and that otherwise
comply with the notications and disclaimer provisions of x 101.93(a) through (e), including the
requirement that any structure/function statement be substantiate.25
The proposed denition of diseased is more thorough than under previous acts, rules, and regulations, and,
as it turned out, a controversial sticking point. Some claimed that the new denition would essentially
prevent all structure/function claims on the labels of dietary supplements.26 The FDA chose to formulate
a denition which diered from the NLEA's denition, a denition \based on standard medical and legal
denitions of the term"27: \Under the proposed x 101.93(g)(1), a \disease" is any deviation from impairment
of, or interruption of the normal structure or function of any part, organ or system (or any combination
thereof) of the body that is manifested by a characteristic set of one or more signs or symptoms."28 In order
23Id. at 23625-23636
24Id. At 23625.
26Dietary Supplement Health and Education Act: Is the FDA Trying to Change the Intent of Congress? Supra note 3, at 69.
27Id.
28Id
13to avoid inconsistency, the FDA proposed an addition denition of \disease" or \health-related claim" under
x 101.14(a)(6):
...[A disease or health-related condition is dened as] any deviation from, impairment of or inter-
ruption of the normal structure or function of any part, organ, or system (or combination thereof)
of the body that is manifested by a characteristic set of one or more signs or symptoms (including
laboratory or clinical measurements that are characteristic of a disease), or a state of health leading
to such deviation, impairment, or deviation; except that diseases resulting from the essential nutrient
deciencies (e.g., scurvy, pellagra are not included within this denition or x101.70)."29
The FDA considered this change is the denition of disease because it found the NLEA's requirement of
\damage" to be so narrow as to not consider some conditions as diseases that are typically considered as
so by the medical profession. In the proposed rule, the FDA notes that the proposed denition for x 101
14(a)(6) was broader than that proposed for x 101.93(g)(1). This denition proved critical as it distinguished
the line between \disease claims" and \structure/function claims"30 In noting the distinction, the Agency
explains that the denition in x 101.14(a)(6) is intended to cover both diseases and \health-related condi-
tions," thereby requiring the expanded denition.31 Ironically, it is exactly that broadening of the denition
of disease that creates the most controversy for the FDA's proposed rule.
In its proposed rule, the FDA also dened the criteria for identifying a disease claim. The FDA provided
illustrations of statements which it would and would not consider to be disease claims, with all statements
considered in context. Proposed x 101.93(g)(2)(i) classies a statement as a disease claim if it claims an \eect
on a specic disease or class of diseases." Examples of disease claims under the proposed x 101.93(g)(2)(i)
include \'protective against the development of cancer,' `reduces the pain and stiness associated with
arthritis,' `decreases the eects of alcohol intoxication,' `or alleviates constipation."'32 Examples of struc-
ture/function claims would include \'helps promote urinary tract health, 'helps maintain cardiovascular
30Bass & Raubicheck, supra note 12, at IV 5.
3152 Fed. Reg. 23624, 23626.
32Id.
14function and a healthy circulatory system,` `helps maintain intestinal oral,' and `promotes relaxation."'33
The FDA identies these statements, at least preliminarily, as structure/function statements as they are
broad and fail to refer to specic diseases.
The proposed rules then identies statements which would and would not be acceptable under the proposed
denition of disease (statements which explicitly or implicitly refer its eect on a disease or symptom) under x
101.93(g)(1) include \'improves urine ow in men over 50 years old' (characteristic symptoms of, e.g. benign
protatic hypertrophy); `lowers cholesterol' (characteristic sign of, e.g. hypercholestemia); reduces joint pain'
(characteristic symptoms of, e.g., arthritis); and `relieves headache" (characteristic symptom of, e.g., migraine
or tension headache)."34 As to the previous examples, it is the specicity of the symptoms mentioned
that disallow these statements. Statements which would be allowable and considered structure/function
statements (not referring to specic diseases would include \'reduces stress and frustration,' `inhibits platelet
aggression,' and `improves absentmindedness."'35 The prior statements are considered broad enough as to
not refer to specic diseases. The FDA recognizes that \there can be disagreement about circumstances in
which a reference to maintaining normal function implies disease treatment or prevention,"36 and it sought
comments on the issue.
The FDA next seeks to explain that claims made regarding natural states (e.g., aging, pregnancy) may be
considered disease claims in some circumstances, a second, related issue raised in the proposed rules which
raised a re-storm of controversy. These states \are sometimes associated with abnormalities that are charac-
33Id.
34Id.
35Id.
36Id.
15terized by a specic set of signs or symptoms, and thus meet the proposed denition of disease."37 Examples
of disease claims under these criteria might refer to the symptoms of toxemia, premenstrual syndrome or
Alzheimer's disease. Acceptable structure/function statements would refer to conditions generally with no
mention of specic abnormalities, signs or symptoms.
The proposed rule indicates that a variety of aspects of a product's label may be considered, under x
101.93(g)(2)(iv), to be disease claims. Explicit or implicit claims may be made in a product's name, by
claims about its formation, by citing a publication in which the title names a specic disease, or use of the
word disease, or \by use of picture, vignettes, symbols, or other means" which suggest an eect on a disease.
38 The use of some product class names may be considered to be disease claims through association with a
specic disease under the proposed rules: \...[S]tatements would be considered a disease claim if it claimed
that the product belonged in a certain class of products recognizable to health care professions or consumers
as intended for use to diagnose, mitigate, treat, cure, or prevent a disease."39 A statement might also be
considered a disease claim if it claims a similarity to a drug or disease treatment intended to treat a disease
or if it suggests that the product should be used in conjunction with such a drug or disease treatment. These
types of claims imply that the eect of the product is similar to that of recognized drugs or treatments, and
are, therefore, to be considered disease claims. Claims which are general in nature, not mentioning a specic
drug or therapy are, again, considered structure/function claims.
Other claims which would be considered disease claims under the proposed rules are those that suggest
that a product can be used to enhance the body's own natural \disease ghting capabilities."40 Under this
criterion, a statement would be considered a disease claim if it refers to a normal bodily response to disease
37Id. at 23627.
38Id.
39Id.
40Id.
16or the bodily ability to prevent or mitigate the eects of an infectious disease or pathogen. Acceptable
structure/function claims may refer to a generalized bodily system with a variety of functions.
Additionally, statements which claim an eect on side eects of drugs or disease treatments are also considered
disease claims. These claims are interpreted under the proposed rule because, similar to a claim which
suggests a product should be used in conjunction with a drug or disease treatment, these types of claims
infer that they should be used in the initial treatment plan for a disease. The mere mention of a therapy for
a disease makes a statement a disease claim, while claims which do not mention a therapy do not. Finally,
the proposed rules include a \catch-all" category which states that \[u]nder proposed x 101.93(g)(2)(x), a
statement would be considered a disease claim if it otherwise suggested an eect on a disease or a class of
diseases."41 The inclusion of this nal criterion for identifying disease claims leaves the FDA with a good
deal of wiggle room in its ability to broadly dene the characteristics of disease claims.
As required when promulgating regulations, the FDA included the typical citation of legal authority, the
eective date of the proposed rule and its plan for implementation, an environmental impact statement, a
statement on the expected economic impact of the proposed rule (cost-benet and small entity analyses)
and a request for comments.
Reaction to the Proposed Rules
Reaction to the proposed rule was swift and harsh. The FDA was inundated with over 100,000 comments
(all of which it was obligated to take into account) from the public, manufactures, academics, medical
professionals attorneys and other interested parties. Based on these reactions, there was also a general
41Id. at 23628.
17outcry in professional journals and other publications. The Committee on Government Reform in the House
of Representative held a hearing on March 25, 1999 to determine whether the FDA was attempting to thwart
Congress, intent in passing the DSHEA with its proposed rule
Congress' Intent
Critics have noted various attempts by the FDA to thwart Congress' intent in implementing regulatory
structures for dietary supplements. The Proxmire Vitamin Mineral Amendment of 1976 stated that the FDA
may not establish maximum limits on vitamins or mineral potency, classify a vitamin or mineral as a drug
based on its potency, or limit combinations of vitamins or minerals. However, [a]lthough [the amendments
were] signicant for establishing a precedent, the 1976 amendments had little impact on the FDA's aggressive
regulations of dietary supplements."42 Similarly, the NLEA allowed the FDA to pronounce the regulations of
health claims. The FDA, in implementing the Act, established that the requirements of health claims would
be the same for conventional foods and supplements, consequently disabling Congress' attempt to loosen the
regulation of dietary supplements. The DSHEA was Congress' reaction to this regulatory eort, which both
incapacitated the FDA's regulations and sent a clear message of the congressional intent to restrict the FDA
under the NLEA.43
As noted above, the FDA's proposed rules garnered intense scrutiny in Congress. The House of Represen-
42Kaczka, supra note 4, at 475.
43Dietary Supplement Health and Education Act: Is FDA Trying to Change the Intent of Congress? Supra at note 3, 23628.
18tatives held a hearing in March of 1999 entitled \Dietary Supplement Health and Education Act: Is the
FDA Trying to Change the Intent of Congress?" As could easily be divined from the title of the hearing,
the Committee sought to discover whether the FDA, in its implementation of the DSHEA was thwarting
Congress' intent as indicated by the DSHEA.
The topics of discussion at the hearing were varied. The Committee discussed issues such as the FDA's
promulgated rules regarding nutrition labeling, the FDA's lack of attention to good manufacturing stan-
dards, authoritative health claims, recent court decisions, and specic supplements which raised the concern
of Congress. For our purposes, the Committee's discussion of the FDA's proposed rules regarding struc-
ture/function statements is of the greatest import. Congress' concerned are summarized as follows:
In April, 998, the FDA published a proposed rule dening the types of statements that can be
made concerning the eect of dietary supplements on the structure or function of the body.
This is one of the cornerstones of the Dietary Supplement Health and Education Act which
allows for statements on structure and function, but prohibits claims that supplements treat
or prevent disease. The agency received over 100,000 comments regarding this issue which
clearly indicates the proposed regulation is fraught with problems. Of particular concern
is that the FDA redened the word disease" in such as [sic] manner that it could include
conditions such as aging, menopause, and pregnancy. This new denition so broadens the
denition as to exclude any useful structure function statements. If this rule became nal,
it would be in direct contradiction to the Dietary Supplement Health and Education Act's
intent of improving the amount of information available on labels and in labeling.44
Of particular interest, in this statement, is that Congress has foreshadowed, so to speak, the future of the
FDA's proposed rule on structure/function claims.
The hearing focused on the proposed rule on structure/function claims. In Congress' view, its intent in pass-
ing the DSHEA was to allow dietary supplement manufacturers to make such structure/function statements
in order to better inform the public about the benets it can expect in consuming a product which will
19support the structure or function of the body. The introductory statement of the hearing noted that: [t]he
proposed rule would supersede legislation passed by the Congress and be in direct opposition to the will of
Congress and the American people." In a rather responsive statement, one commentator noted that \[w]hile
some have argued that DSHEA is full of complex questions of fact, policy and law, it is the duty of the FDA
and its Commissioner to enact DSHEA and provide the American consumer with safe and regulated dietary
supplements."45 Some members of the Committee even suggested that the \FDA is deliberately suppressing
information which could help health consumers make an educated decision about products which could help
them. The FDA limits what producers of health supplements ma say about their products."46
Attorney Scott Bass, a noted expert on food and drug law, sets out four basic points which criticize the
FDA's proposed rule for attempting to thwart the intent of Congress:
A.
FDA tried to put the word \normal" back into Section 6 after Congress kept it out.
FDA proposes to redene the word \disease" so that \disease" would be dened as any
interruption or impairment of \normal structure or function.... During the negotiation
leading to the passage of DSHEA, there were some eorts to insert the word \normal" in
the structure/function section. Those eorts were met with strong resistance and Congress
chose to leave it out. For this reason alone, the proposed regulation signicantly undercuts
the benet of Section 6.
B. The new \disease claim denition can make almost any claim illegal.
... FDA's redenition of \disease claims" renders a dietary supplement illegal if a product
claims an eect on \one or more signs or symptoms constituting an abnormality of the
body." It is not dicult to imagine that some symptoms might be \recognizable to health
care professionals" as referring to normal or abnormal people { e.g[.], a pregnant woman, a
woman enduring menopause, an aging individual or a person with allergies.
45Id. at 25.
46Id. at 59.
20C.
The \disease claim" denition renders all dietary supplement manufacturers defenseless.
... All the FDA has to prove is that a health care professional \recognizes" that a dietary
supplement claim \implicitly... has an eect on a consequence of a natural state" that
the health care professional thinks is an implicit reference to an abnormality.... [I]n prac-
tice, [that] means the defendant loses. If the FDA obtains the adavit of one health care
professional, the Agency would carry the day....
D.
Congress required a structure/function disclaimer to inform consumers
that the product had not been approved by FDA and was not intended to treat or cure disease. The proposal renders that disclaimer useless.47
Clearly, Mr. Bass considers the proposed rule as an attempt by the FDA to frustrate the entire congressional
motive for passing the DSHEA, to provide the public with much needed information in a blossoming dietary
supplement market. Others made similar claims: \The current proposal appears to be a stubborn attempt
to reverse the major provisions of DSHEA and prevent most statements of nutritional support."48 Further,
\Congress specically rejected limiting structure/function claims to the `help maintain' or `promote healthy'
structure/function variety when it enacted DSHEA. Rather Congress intended to permit claims that describe
the role a nutrient plays in the body."49 Similarly, the proposed rule would disallow some claims about natural
states of being, considering them disease claims, while Congress intended these types of statements to be
permissible.50
Criticism of Proposed Rule
48Id. at 117.
49Id.
50Id.
21Congress saw the proposed rule as a \regulatory sleight-of-hand to stie such statements."51 It was clearly
a dicult thing to draw the line between structure/function claims and disease claims under the DSHEA,
but some felt that \[i]t [was] even more complicated [when] the FDA, historically biased toward thinking
things are drugs, proposed implementing regulations that dened \disease" broadly, making it harder to
formulate a structure function claim that is permissible."52 Others suggested that the \agency proposes to
do through administrative at that which Congress refused to do expressly, limit structure/function claims
to \maintaining" or \promoting" healthy bodily structure or function claims."53 These comments focused
on the fact that, while the DSHEA requires a distinction to be drawn between structure/function claims and
disease claims and that such a distinction may be dicult to make, the FDA failed, in fact, to draw such a
clear distinction between these types of claims.
One critic noted that the FDA had not furnished any legal basis supporting its authority to change the
denition of disease in its proposed rule.54 Another noted that the FDA's actions seemed to be a mere
power grab.55
An additional criticism of the rule's labeling requirement focuses on the sheer diculty in overcoming
regulatory-induced dilemma presented to manufacturers in the proposed rule: \FDA establishes a \con-
sumer intent of use" basis for reclassifying a dietary supplement as a drug based on how a consumer intends
to use a product { even if it is properly labeled with an allowable structure/function statement.56
Most of the 100,000 comments and focused on the FDA's re-denition of \disease." (The FDA received an
additional 200,000 consumer letters critical of the proposal).
Criticism of the proposed re-denition of disease also came from other sources. For example, in a letter from
51Dietary Supplement Health and Education Act: Id the FDA Trying to Change the Intent of Congress? supra note 3, at 69.
52Greenberg, supra note 9.
53Todd Harrison, \FDA Continues to Struggle with the Permissible Breath of Structure/Function Claims. Denition of Disease
Still Subject to Debate." http://www.khlaw.com/nutra/html. (7/15/00) at note 48.
54Dietary Supplement Health and Education Act: Is FDA Trying to Change the Intent of Congress? Supra note 3, at 120.
55Id. at 122.
56Id. at 123.
22Representative Daniel Burton to Michael Friedman, Representative Burton suggested that the denition is
too broad and would include statements made about some natural states would be considered disease claims
under the proposed denition.57 Other critics note that: \'[t]here is no such thing as a normal body' and
because `[v]irtually anything is a deviation from a normal body,' a literal interpretation of this denition
would eectively mean that `there [is] no such thing as a structure/function claim' and that all claims are
disease (drug) claims.58
In response to the concerns regarding the re-denition of disease, the FDA held a panel discussion about
whether the denition was adequate, The panel was held on August 4, 1999, revealing a division between
interest parties on the topic of whether \damage" should be an issue in dening disease. Some recognized
that the new denition of disease diered considerably from that of the NLEA by deleing of damage which
interferes with proper functioning requirement, requiring a mere deviation. These panelists showed concern
about the deletion of the damage requirement because any deviation from normal functioning, even if natural
or otherwise short-lived could be considered a disease. Others took an opposite view that the denition was
not broad enough, that it discounted deviations that were not typical of disease, but nonetheless, typically
may require medical attention (e.g., constipation) and that many conditions, in their early stages would not
meet the FDA's denition of disease. Still others were concerned about the protection oered to consumers
by the new denition. This panelist focussed on a denition which would disallow claims if consumers were
unable to adequately evaluate them.59 Most panelists agreed that the severity of a condition should not be
the criteria which determines the type of claims which can be made under the structure/function criterion.
Some panelists felt that the typicality of an association of a symptom with an associated pathology would
be a better test that severity (some noting, however, that even this test may rule out some conditions which
57Michael Cohen, U.S. Dietary Supplement Regulation: Belief Systems and Legal Rules, 11 Hastings Women's L.J. 3, 21 (Winter,
2000).
58Laura A.W. Khatcheressian, Regulation of Dietary Supplements: Five Years of DSHEA, 54 Food & Drug L.J. 623, 639 (2000).
59Richard O. Wood, Erik F. Dyhrkopp & Andrew H. Kim, Panel Debates New Dietary Supplement Regulations, 11.29.99 Nat'l L.
J. B12. (col. 1).
23can be considered disease). Finally, panelist discussed their concerns regarding the FDA's eort to clarify
what would be considered an implied disease claim. The FDA oered examples of implied claims in the
proposed rules, but the panelists had diculty distinguishing between the examples oered.60 The panelists
seemed to reect similar concerns as put forth in the comments written to the FDA.
Still others criticized the examples of acceptable statements oered by the FDA, nding them rather silly:
\Thanks to `clarication' by federal regulators, consumers of dietary supplements will have better infor-
mation when they seek `to improve their absentmindedness' or `maintain their healthy intestinal ora'....
[S]ome of the FDA's examples are bound to keep manufacturers and consumers alike at least as confused
as before, if not more so."61 Some of the examples require \mental gymnastics" to understand while others
are actually incomprehensible.62 The examples oered are, at times inconsistent or ambiguous to the extent
that they belie their purpose, to provide guidance to manufacturers.
Other critics called the criteria for dierentiating between a claim of health promotion and a statement
claiming disease prevention capabilities were too narrow and potentially misleading:
FDA's examples of \lowers cholesterol" versus \helps maintain a healthy cholesterol" high-
light the ambiguities inherent in FDA's proposed construct of disease claims under proposed criteria
#2 and #3. What is healthy cholesterol, but a lower cholesterol level? The FDA-dened disease-
related endpoint is a lowering of, presumably, a higher cholesterol level; the health-related endpoint
is maintenance of a \healthy" cholesterol level { which itself is a \lower" cholesterol level generally
recognized as the goal of disease prevent.63
Part of the problem may be that the regulations are to apply to both vitamins and herbal remedies, even
though they may be used for very dierent purposes: \[T]rying to fashion a one-size ts all solution for an
industry with very dierent types of products does not work."64
60Id.
61Michele Simon, Still Cloudy with Little Chance of Clearing: FDA's Proposed Rule on Structure/Function Claims for Dietary
Supplements, 11 Hastings Women's L.J. 23, 23-24.
62Id. at 24.
64Simon, supra note 62 at 25.
24Focusing on the product's intended purpose brings another criticism: "There is simply no getting around
the reality of consumers turning to dietary supplements for treatment-related purposes. The FDA's attempt
to bury its head in the sand and pretend this is not happening because manufacturers are not allowed to
label or market [their] products as such is both irresponsible and futile."65
Supporters of the Proposed Rule
On the other hand, some members of the Committee provided support for the FDA's actions:
Today we will hear arguments that Congress did not intend for the FDA to have an active
role in protecting the consumer from dangerous products being sold as dietary supplements.
We will also hear that FDA's recent eorts to protect the consumer are inappropriate and
heavy-handed intervention. This is simply erroneous. When we passed DSHEA, we knew
that many dietary supplements, such as minerals and vitamins, can play an important role in
promoting health. But, we also know that, without proper regulation, dietary supplements
can sometimes be lethal.66
The commentator continued with the idea that \the agency is trying its best to implement a complex and
ambiguous law."67
Rather than criticize the FDA's eorts, the supporter has a suggestion to ameliorate the controversy: \The
answer isn't to criticize the agency for failure to adhere to the intent of Congress when, in fact, the agency is
trying its best to implement a complex and ambiguous law. Instead, the answer is to establish a regulatory
framework for dietary supplements at FDA that appropriately balances the interests of consumer access and
public health."68 Still another claimed that the proposal's criteria for making structure function claims was
65Dietary Supplement Health and Education Act: Is the FDA Trying to Change the Intent of Congress? Supra note 3 at 123.
67Id. at 18.
68Id. at 18.
25too narrow [implying that the FDA's eorts were appropriate: "General references to bodily functions can
still imply usefulness to prevent disease conditions, and especially so when the claims refer to bodily organs
and functions that normally receive medical attention.69
These supportive comments reect early criticism of the DSHEA and its attempt to deregulate the dietary
supplement market. Critics complain that \"DSHEA has severely limited FDA's power over vitamin safety
and the validity of benet claims.... Congressional removal of most FDA enforcement powers in the 1994
DSHEA has wiped out the FDA's power to require preapproval and claim substantiations and has sharply
reduced regulators' options."70
Final Rule
In publishing its nal rule entitled \Regulations on Statements Made for Dietary Supplements concerning
the Eect of the Product on the Structure or Function of the Body," the FDA noted that in publishing
its proposed regulations to identify and distinguish structure/function claims and disease claims, it received
over 235,000 responses to the proposed regulations. Most of the submissions were form letters, but 22,000 in-
dividual letters were submitted from \the dietary supplement industry, trade association, health professional
groups and consumers."71 Most of the general comments objected to the proposed regulations, stating that
the regulations were too conning. Those who approved of the proposed regulations (mainly health care
professions) felt that the rules were impartial and fair, although some recommended more restrictive regula-
69Id. at 138-139.
70James T. O'Reilly, Dietary Supplement Regulation Constrained by Political Chains, 8-WTR Experience 20, 21 (Winter, 1998).
71Regulations on Statements Made for Dietary Supplements concerning the Eect of the Product on the Structure or Function of
the Body, 21 CFR Part 101, 65 Federal Register, 1000 (200).
26tions.72 Although, in publishing its nal rule, the FDA discusses and responds to hundreds of the comments,
we will focus on specic areas for our purposes, specically, the general comments structure/function state-
ments, the denition of disease, disease claims, the eect on a disease or class of diseases, signs a symptoms
of disease, conditions associated with natural states
In regard to general comments, many that were critical of the proposed regulations felt that \the proposed
rule would curtail or restrict [truthful information] or restrict the focus of dietary supplements to preven-
tive care and wellness...."73 These commentators focused on choice, consumer responsibility, autonomy,
self-education and suggested that a dierent standard \a `truthful and not misleading' standard" or a \full
disclosure" standard.74 Others were concerned that the proposed rules would lead to confusion and less
information would be available to consumers, contrary to Congress' intent. These commentators said the
new regulations would prevent harm, misinformation, suering, monetary loss and may produce a false sense
o security, making consumers unlikely to seek or maintain medical support.75 The FDA agreed that many
of observations were valid, but maintains that the DSHEA did, indeed, advance Congress' intent of provid-
ing consumers information regarding dietary supplements and notes that the nal rule allows some of the
statements which would have been disallowed under the proposed rules to be made without pre-approval.
The FDA also notes that manufactures are subject to a \truthful and not misleading" standard elsewhere
in the rules, so adoption of that standard is unnecessary.
Other comments spoke on the issue of safety of dietary supplements. Many claimed that regulations regard-
ing labeling of dietary supplements are really unnecessary, as the supplements themselves are safe. Other,
however, noted that dietary supplements might give consumers a false sense of security, perhaps leading
to dangerous results. The FDA agrees that safety is the motivation behind the rule and that mislabeling
72Id.
73Id. at 1002.
74Id.
75Id.
27poses a risk to consumers. Additionally, although the FDA regards many dietary supplements as safe, it
recommends further studies to determine the safety and eectiveness of some supplements.76
The comments reveal an addition charge that the \FDA had no authority to issue the proposed rule because it
was inconsistent with DSHEA and congressional intent, in that it restricted rather than increased the amount
of information given to consumers."77 As noted in the discussion above, many feel that Congress passed the
DSHEA as a result of the FDA's over-regulation of dietary supplements. The FDA agrees that Congress'
intent regarding the DSHEA was to allow for more information to be oered to consumers, and points to
changes in the nal rule which address these concerns, \including a return to the preexisting denition of
\disease or health related condition" and a less restriction interpretation of the types of structure/function
claims that can be made about conditions associated with natural states such as aging, pregnancy and the
menstrual cycle."78 The FDA does note that separate authority is not required for the promulgation of the
rule, and it also reiterates the fact that disease claims are still reviewable under the nal rule.
Still others claim that the FDA did not adequately justify the basis for issuing the rule. Some argued that
the FDA did not adequately consider the Commission's report when developing the proposed rule and that
the DSHEA is self-implementing. The FDA counters than under 701(a), it did have the authority to issue
the rule and bases this claim on the fact that sucient confusion exists among consumer and manufacturer
confusion exists to justify the promulgation of the rule, and hence, the DSHEA is not self-implementing.
The FDA also notes that the Commission's support of the proposed rule was not necessary.79
One comments notes that the proposed rule should have been crafted in a manner to avoid overlaps between
structure/function claims and disease claims, but the FDA responds that while some statements, on their
face, may resemble structure/function claims, they are, in essence, disease claims, so there can be no concrete
76Id. at 1003.
77Id.
78Id. at 1003-1004.
79Id. at 1004-1005
28distinction.80 Others agree that it is not possible to draw such a distinction, and the FDA notes that it
eorts are statutorily required.81
Some commentators feel that the rule would chill scientic research, but the agency says there is no evidence
to support this claim. Still other feel that the proposed rule would impact drug development, some feeling
that it was a pro-pharmaceutical action, while others feel it would have a negative impact on development
of such products. The FDA also disagrees with this charge.
Additional comment demonstrate concerns that dietary supplements may be classied as drugs if the state-
ments made on the label, or other evidence, could be considered by consumers to be disease claims. The
FDA applies that such evidence is not considered in isolation. Consumer intent alone would not be used to
classify a dietary supplement as a drug.82
Other commentators express concern about the disclaimer requirement under the proposed rule. While some
feel that the statement resolved consumer confusion, others felt that the disclaimer was inconsistent with the
proposed rule (in that a disclaimer is not necessary if the proposed rule so limits structure/function claims
as to make them unavailable). The FDA disagrees, saying \the disclaimer's role does not eliminate the need
for this nal rule to establish criteria for determining whether a statement is a disease claim."83
Some comments seek additional labeling requirements for dietary supplements, although while the FDA
states that the Act suciently addresses these concerns. The FDA also refers to its consistent use of the
term claims and \statements" as equivalent despite concerns that the term \claim" may be pejorative.84
Still others demonstrate concern that unless some supplements were classied as drugs, non-reviewed po-
tency levels and the lack of scientic evidence of safety raise concerns about the harmful eects of essentially
unregulated supplements. However, despite the tone of the proposed rule, the FDA asserts that some \health-
80Id. at 1005.
81Id.
82Id. at 1006
83Id. at 1007.
84Id.
29related" claims are acceptable under the structure/function claim criterion.85
Still other comments complained that the proposed rules criterion were too subjective. The FDA responds
by modifying one of the criterions to a more objective standard. 86 Others object to the regulation of any
statement or claim which referred to a \nutrient content claim or claims pertaining to a classical nutrient
deciency-related disease."87 In addressing this concern, the FDA states that the nal rule already provides
an exception to claims which refers to a classical nutrient deciency disease. Many suggest that the FDA
should issue guidance documents in lieu of the proposed rule. The FDA disagrees, noting that the regulations
provide uniform requirements to all members of the industry. Another solution is oered to the FDA to
merely enforce existing laws which focus on supplement safety, rather than promulgate regulations. However,
the FDA notes that regulations provide a valuable tool in the regulation of dietary supplements.88
Other alternatives to promulgating regulations are made. Others suggest that the FDA lacks the expertise
to classify botanicals, and others pointed to the regulation of dietary supplements in other countries as an
alternative. The FDA, in rejecting these ideas, also notes that the FDA would be issuing guidance documents
to address many of these concerns.89
The FDA provide no response to comments discussing the issue of permitted structure/function claims,
noting that it had modied x 101.93(f) \to make it clear that a dietary supplement may bear a disease claim
if it is the subject of an authorized health claim, but that otherwise disease claims will subject the product
to treatment as a drug."90
The FDA proposed denition of disease in x 101.93(g)(1) results in many comments. The FDA re-opened
the comment period, and sought additional comments on the following issues:
85Id.
86Id. at 1007-1008.
87Id. at 1008.
88Id.
89Id. at 1008-1009.
90Id. at 1009
30(1)
What are the consequences with respect to the range of acceptable structure/function claims: (a) The 1993 denition in x 101.14(a)(5), or (b) the denition of the proposed rule?
(2)
If the FDA were to retain the 1993 denition, does the reference to \damage," exclude nay conditions that are medically understood to be diseases? Please provide examples.
(3)
If it does not exclude any such conditions, is the 1993 denition otherwise consistent with current medical denitions of disease?
(4)
If it does exclude conditions that are medically understood to be diseases, could it be revised in a way that would include such conditions?91
Nearly all comments protest the proposed denition of disease, many calling it too broad. Some suggest that
changing the denition clearly frustrated congressional intent.92 Other comments suggest a return to the
1993 denition, but those in the medical community supported the new denition. Others suggest a dierent
denition altogether (seemingly following the interests of the group to which they originate) or advocated
a \common sense" approach. In response to the to he negative comments, the FDA concludes that the
1993 denition would not exclude any disease conditions, and, as such, declined to enter a new denition
of disease in the nal rule.93 Another suggests that the denition should be crafter so as to not include
health-related conditions which do not require drug or medical treatments. The FDA responds that there
is no congressional intent demonstrated which would call of subsets for diseases to be established. Finally,
another commentator suggested that the 1993 denition t well with consumer understanding.94
92Id.
93Id. at 1010.
94Id. at 1010-1011.
31As to comments discussing disease claims under x 101.93(g)(2), many comments agree that a claim should be
examined in the light of total circumstances. Others feel the rule was biased or vague. The FDA recognizes
competing goals in the comments and states that the nal rule attempts to address these competing goals.
Another comment suggest a rule which draws a correlation between the eects of a dietary supplement
on a condition and the eects of a conventional food on the same condition, but the FDA notes that the
claims should be product specic. Another suggests that any claim should be allowable which is not already
considered a drug claim. The FDA counters, however, that not all drug claims are disease claims, so this
distinction is not appropriate.95 Finally, others suggest that the claims permitted under the proposed rule
could not be substantiated. The FDA agrees that this applies to some claims, but believes that such claims
fall within the scope of the provision and notes that substantiation of such claims would not be impossible.96
Numerous comments focus on the eects on disease or class of diseases under x 101.93(g)(2)(i) which pro-
posed that a claim would be considered a disease claim if it claims eects on disease. The FDA had sought
additional comments on this issue during a public hearing concerning this section, oering examples of claims
to be commented upon. It also four questions in response to the examples:
(1)
If implied disease claims should be permitted, has FDA correctly drawn the line between what constitutes an express disease claim and what constitutes a permitted implied claim? (2) If such claims should be permitted, what are representative examples of the types of implied disease claims that should be permitted without prior review (3) Are the examples of implied claims mentioned in the July 8 notice appropriate structure/function claims? (4) Is a claim that a product `maintains healthy function' an implied disease claim in all cases? If not, under what circumstances is such a claim not an implied disease claim?97
Many of the resulting comments feel that structure/function claims should, indeed, not mention diseases,
citing consumer confusion and danger. But, others contend that implied disease claims should be allowed
95Id. at 1011.
96Id. at 1012.
32if they are truthful, arguing congressional intent or the narrowness of the proposed rule. In response,
the FDA notes that its stance has not changed, that implied disease claims should be disallowed, citing
congressional intent: \Congress did not... create any exemption from section 201(g)(1)(B) of the act for
dietary supplements. Thus, dietary supplements that are `intended for use in the `diagnosis, cure, mitigation,
treatment or prevention of disease' are subject to regulation as drugs under the act,"98 the intent mentioned
being an objective one. Allowing implied disease claims to be structure/function claims would both belie the
FDA's interpretation of the provision and would also \conict with the health claim scheme established [by
the act]."99 The FDA cites case law and statutory provisions to support its view, asserting that those cases
cited in the comments fail to support the suggestions oered. It also is not persuaded by the commentators'
interpretation of congressional intent or the intent of the Commission, as indicated by the totality of the act
and the Commission's report. The FDA also disagrees with some comments which suggest that the disclaimer
provision shows a congressional intent to allow for implied claims, noting that the required language in the
disclosure would be inconsistent or contradict with an implied claim.100 The FDA responds that there is no
evidence of this in the construction of the act and no consumer research to support such a conclusion.
Others, as previously noted, suggest that under the proposed rules, it would be impossible to write an
acceptable structure/function claims, and the FDA points to its examples in response. Some comments
insist that the examples for disease claims discussed states, such as intoxication, which cannot be considered
diseases. The FDA notes that intoxication is a form of poisoning and, thus, can be considered a disease.
Finally, the FDA notes that the use of a professional organization's endorsement (which contains the name
of a disease) would result in a disease claim based on the totality of the labeling.101
The FDA then addresses x 101.93(g)(2)(ii) regarding signs or symptoms of disease. The section classies
98Id. at 1014.
99Id.
100Id.
101Id. at 1015.
33claims as disease claims if they refer explicitly or implicit to signs or symptoms typically associate with a
disease. Objecting comments claim this proposal is also vague. They were concerned that the rule refers
to consumer recognition of a sign or symptom associated with disease. Some note that this would make
comments a \moving target" subject to changing consumer information. The FDA responds by oering a
more objective criterion in the nal rule. The nal rule eliminates the recognition requirement and replaces
it with a criterion which asks \simply... whether the labeling suggests that the product will produce a change
in the characteristic signs or symptoms of a specic disease or class of diseases."102 The FDA notes that
this test makes it easier to recognize what will be considered a sign or symptom.
Others argue that all signs or symptoms can be recognized as relating to a disease, especially for health care
professionals. Others feel them to be arbitrary. Still others say signs or symptoms can be related to a number
of conditions, not only diseases. The FDA points to the nal rule (as noted above) which deletes reference
to recognition to address these concerns. Others (some of whom object to the disease denition) say that
merely because a sign or symptom is named in a disease denition, it does not follow that mentioning the
sign or symptom in a claim should make it a disease claim, noting that the same does not hold for drug
claims. The FDA argues that the denition of disease in the nal rule does not refer to signs or symptoms,
but claims that mention them will still be considered disease claims. The FDA also notes that the mention
of the sign or symptom in the denition of a certain disease does not change the objective criterion it will
use.103
Other comments complain that the line between maintaining a healthy function and treating abnormal
function is \articial,"104 that consumers make no such distinguish. Some insisted both types should be
allowed while others (health professional) said that neither claim should be allowed. The health professions
102Id. at 1006
103Id. at 1007.
104Id.
34want claims which implied the prevention or treatment of disease to be considered disease claims (some
suggesting that such statements would hamper the development of orphan drugs by undercutting the sales
of such drugs). The FDA cites congressional intent by pointing out that the statue does distinguish between
maintains healthy function and treats abnormal function claims. The FDA does maintains that the DSHEA
considers abnormal function claims to be disease claims.
Other comments note that the FDA had not established the distinctions between the structure/function
examples and disease claim examples it had oered, citing the cholesterol examples. The FDA said the men-
tion of cholesterol in a claim would not classify it as a disease claim if was a maintenance claim that makes
no mention of \lowering" cholesterol, as cholesterol plays a positive role in the body. Th FDA points at
congressional intent again. Another comment expresses the opinion that \lowers cholesterol" claims should
be allowed to provide the public with information on eective alternative, but the FDA believes this would
pose a risk as some consumers may delay medical treatment. The FDA maintains that it had the experience
and extensive evidence to support its decision.105
The comment section included a lengthy discussion of constitutional issues involved in the proposed regula-
tions. For our purposes, the discussion of First Amendment issues is especially enlightening. Some comments
claim that \the rule violates the First Amendment because it is more restrictive than is necessary to ad-
vance FDA's interests"106 (see below for further discussion of this issue). These comments noted that the
FDA may not prohibit statements which are not misleading, and the government may only regulate to the
extent necessary to advance its interests. Because not all structure/function claims are false and misleading,
this may overcome the FDA interests, even though substantial, claim these comments. Others claim the
disclaimer requirement violates free speech rights.
Others focus on another issue: \[T]he proposed rule violates the First Amendment because, using the anal-
105Id. at 1019.
106Id. at 1037.
35ysis in Central Hudson Gas & Electric Corp. v. Public Service Commission, 447 U.S. 557 (1980), it is
not narrowly tailored to meet the FDA's interests and does not directly or materially advance the agency's
interests."107 Others are concerned that the FDA had failed to identify adequately its interests or shown
that any of the claims were misleading. Some comments suggest that the proposed rule represent a \prior
restraint" on free speech. Still other comments claimed that the proposed rule is contrary to the holding
in Pearson v. Shalala, 164 F.3d 650 (D.C. Cir. 1999). According to the comment,\ Pearson requires the
agency to permit health claims that do not satisfy the `signicant scientic agreement' standard as long as
the claim can be rendered non-misleading by requiring a disclaimer."108 This comment suggests that the
FDA had no authority under Pearson to issue the nal rule without modication.109
The FDA responses to these comments are lengthy. It vigorously deny that the rule violates the First
Amendment: The rule does not prohibit any speech; rather, it claries the circumstances under which FDA
will consider certain types of speeches { labeling claims { to be evidence of intended use as a drug."110 The
FDA cites Wisconsin v. Mitchell, 508 U.S. 476 (1993) to support its contention that the Constitution does
allow it to engage in evidentiary use of speech in proving intent.
Additionally, the Agency notes that even of the regulations did restrict speech there would still be no issue
under the First Amendment. The failure of the FDA to enforce this rule and the failure of manufacturers
to follow would create a situation in which unregulated products which could be considered drugs without
the approval process for drugs, an illegal act in itself. The FDA concludes that, as such, free speech rights
would not attach to an illegal product according to the Supreme Court in Central Hudson.111
Nor does the FDA consider the rule to be a prior restraint on speech as it notes above; it is not restricting
speech but using it as evidence of intent. The Agency acquiesces that some claims classied as disease
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36statements are subject to preapproval, including the evaluation of the product's safety and the supporting
evidence for the claim. Additionally, in Central Hudson, the Supreme Court suggested that prior restraint
may not even apply to commercial speech, and permitted the prior review of commercial speech.112 (The
FDA eventually concludes that the rule holds under all prongs of the Central Hudson test.)
The FDA goes on to discuss judiciary support of its regulatory schemes in a number of cases. The FDA
particularly disagrees with the comment which requested no test for claims if accompanied by the disclaimer
in order to improve the information available to consumers. The FDA's stance is that contradictory state-
ments are more likely to lead to confusion.113 A scheme which allows disease claims to be reviewed (rather
than merely accompanied by a disclaimer) ensures that an agency with relatively little bias will review these
claims in order to support the government interest of consumer safety, according to the FDA.
The FDA dismissed the Pearson decision as inapplicable to drugs (although, interestingly it cites a foot-
note). It does give a little more attention to the holding in Washington Legal Foundation v. Henney, 1999
WL 557679 (D.D.C. July 28, 1999), which \concerned the constitutionality of certain provisions of the FDA
Modernization Act of 1997."114 In this case, the subject matter involved the dissemination of information
concerning \o-label" uses for currently approved drugs. The court found the restrictions to be unconstitu-
tional.115 The FDA notes it is appealing this case.
The FDA distinguishes Washington Legal Foundation by noting in that case: 1) there were less restrictive
alternatives, which would advance the government" interest; 2) the language in that case was directed only
toward physicians, not the general public: and 3) the products involved in that case were drugs.116
Other constitutional claims include equal protection under the 14th Amendment and the Takings Clause
112Id. at 1038-1039.
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37under the 5th amendment.117 The FDA points out that the 14th Amendment applies only to the states, but
if the comment was intended to speak to the 5th Amendment, it notes that the comment fails to demonstrate
disparate treatment, and the rule does not eect fundamental rights.118 As to the Takings Clause, the FDA
notes that the test employed by the Supreme Court which examines the character of the government action,
the economic impact of the action and the interference of the reasonable investment-backed expectations,
would demonstrate that the rule can not be considered a taking under the Constitution.119
Further discussion is included referring to product names and formulations, citation of publication titles, the
use of the word disease in a label, pictures and other symbols on a label, membership in a product class,
substitutes for or augmentation of disease therapy, and the role of the supplement in the body's response to
disease. These discussions also consider the treatment/prevention of adverse events, claims not addressed in
the proposed rule, substantiation of claims, enforcement issues and a lengthy discussion of legal authority.
The FDA supports its rule under all of these suggestions.
In short, after reviewing the comments, the FDA made revision in the nal rule which oered the criteria for
identifying when a labeling claim is a structure/function claim and when it is a disease claim. Specically,
in addressing the concerns of the comments, the FDA notes (as previously deleted its proposed denition
for disease. Secondly, the FDA modied it criterion \that applies to conditions associated with such natural
state or processes as menopause, aging, adolescence, and pregnancy...[such c]ommon conditions that do not
cause signicant or permanent harm will not be treated as diseases under the nal rule"120 Finally, the FDA
revised the \criterion that relates to the use in labeling of the titles of publications that refer to diseases....
117Id at 1040-1043.
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38Under the revised criterion, the use in labeling of a publication title that refer to a disease will be considered
a disease claim only if, in context, it implies that the product may be used to diagnose, treat, mitigate, cure
or prevent disease."121 All of these changes are reected in the Agency's nal rule, as follows:
PART 101|FOOD LABELING
* * * * *
x 101.93 Certain types of statements for dietary supplements.
* * * *
(f) Permitted structure/function statements. Dietary supplement labels or labeling may,
subject to the requirements in paragraphs (a) through (e) of this section, bear statements
that describe the role of a nutrient or dietary ingredient intended to aect the structure or
function in humans or that characterize the documented mechanism by which a nutrient or
dietary ingredient acts to maintain such structure or function, provided that such statements
are not disease claims under paragraph (g) of this section. If the label or labeling of a product
marketed as a dietary supplement bears a disease claim as dened in paragraph (g) of this
section, the product will be subject to regulation as a drug unless the claim is an authorized
health claim for which the product qualies.
(g) Disease claims. (1) For purposes of 21 U.S.C. 343(r)(6), a \disease" is damage to
an organ, part, structure, or system of the body such that it does not function properly
(e.g., cardiovascular disease), or a state of health leading to such dysfunctioning (e.g., hy-
pertension); except that diseases resulting from essential nutrient deciencies (e.g., scurvy,
pellagra) are not included in this denition.
121Id.
39(2) FDA will nd that a statement about a product claims to diagnose, mitigate, treat,
cure, or prevent disease (other than a classical nutrient deciency disease) under 21 U.S.C.
343(r)(6) if it meets one or more of the criteria listed below. These criteria are not intended
to classify as disease claims statements that refer to the ability of a product to maintain
healthy structure or function, unless the statement implies disease prevention or treatment.
In determining whether a statement is a disease claim under these criteria, FDA will con-
sider the context in which the claim is presented. A statement claims to diagnose, mitigate,
treat, cure, or prevent disease if it claims, explicitly or implicitly, that the product:
(i) has an eect on a specic disease or class of diseases
(ii) Has an eect on the characteristic signs or symptoms of a specic disease or class of
diseases, using scientic or lay terminology;
(iii) Has an eect on an abnormal condition associated with a natural state or process, if
the abnormal condition is uncommon or can cause signicant or permanent harm;
(iv) Has an eect on a disease or diseases through one or more of the following factors:
(A) The name of the product;
(B) A statement about the formulation of the product, including a claim that the product
contains an ingredient (other than an ingredient that is an article included in the denition
of dietary supplement under 21 U.S.C. 321()(3) that has been been regulated by FDA as
a drug and is well known to consumers for its use or claimed use in preventing or treating
a disease;
C) Citation of a publication or reference, if the citation refers to a disease use, and if, in the
context of the labeling as a whole, the citation implies treatment or prevention of a disease,
e.g., through placement on the immediate product label or packaging, inappropriate promi-
nence, or lack of relationship to the product's express claims;
(D) Use of the term disease or diseased, except in general statements about disease preven-
tion that do not refer explicitly or implicitly to a specic disease or class of diseases or to a
specic product or ingredient; or
(E) Use of pictures, vignettes, symbols, or other means;
(v) Belongs to a class of products that is intended to diagnose, mitigate, treat, cure, or
prevent a disease;
(vi) Is a substitute for a product that is a therapy for a disease;
(vii) Augments a particular therapy or drug action that is intended to diagnose, mitigate,
treat, cure, or prevent a disease or class of diseases;
(viii) Has a role in the body's response to a disease or to a vector of disease;
(ix) Treats, prevents, or mitigates adverse events associated with a therapy for a disease, if
the adverse events constitute diseases; or
(x) Otherwise suggests an eect on a disease or diseases.
Dated October 26, 1999122
The nal rule was, of course, accompanied by a discussion of the implementation plan, the environmental
impact and an analysis of impact. The analysis impact included a cost/benet analysis, costs of compli-
40ance (for labeling redesign and administrative costs, inventory losses, a total direct compliance costs and a
sensitivity analysis).123 For our purposes, no further discussion of these issues is required.
Reactions to the Final Rule
The nal rule is interpreted (and criticized) in the following manner:
The critical distinction in the regulation between a structure/function claim
and a drug claims centers on the denition of the term \disease".... FDA also sets forth
various criteria by which the agency will judge whether or not a given claim is a disease (and
thus a drug) claim. In the preamble to the nal regulation, FDA illustrates by example,
particular disease claims (and acceptable structure/function claims) under these criteria.
These criteria and the examples are somewhat helpful, but they still leave a substantial
gray area. The line between many structure/function and disease claims will be subjective,
and much will depend on wording, context, and interpretation. Also, the preamble is not
the regulation, and the FDA is free to change its mind about particular examples without
amending the regulation.
Furthermore, FDA states that the list of criteria is not exhaustive, and some examples given
for acceptable structure/function claims are claims currently permitted for OTC drugs. This
further blurs the boundary between drug and dietary supplement regulatory categories.124
This commentator also identies the test for identifying what is considered a sign or symptom characteristic
of disease: \The test is whether signs or symptoms characteristic of a disease are mentioned in the claim.
Not every sign or symptom need be mentioned."125 As to the subject of natural conditions, \[t]he key factors
distinguishing a natural state from a disease are a) the severity of the condition, and b) the commonness of
the condition."126
Criticism of the nal rule focuses primarily on the ambiguities left undressed: \While FDA has made a
good faith attempt to distinguish between structure/function claims and drug claims, certain claims that
are acceptable structure/function claims are quite close in language and meaning to claims that are deemed
123Id. at 1044-1047.
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41disease (drug) claims.... Secondly, in a surprising move, FDA has indicated that there are acceptable struc-
ture/function claims that are identical or similar to drug claims in OTC monographs."127 Others claim that
the nal rule leaves unanswered questions: \Does [the rule] apply to oral representations?... Is it enough to
notify the FDA once as opposed to notication for every product for which a particular claim was made?128
Another question which is not addressed is the long-term eects of the use of dietary supplements.129
Suggestions
Both before and after the promulgation of the rule, many critics have oered suggestions for ameliorating
the negative eects of the DSHEA itself and the FDA's nal rule. One critic suggested that the FDA should
consider the impact of under-reporting of the adverse eects of specic dietary supplements and should
require the inclusion of a hotline number on dietary supplement labels in order to promote accurate, timely
reporting of adverse eects.130 This critic also suggested that the \FDA should use its statutory publicity
powers to challenge the marketing of vitamins with misleading health claims."131
Another commentator has suggested that the FDA establish a regulatory scheme which mirrors its regulation
of the cosmetic industry: \The FDA should encourage the dietary supplement industry to establish volun-
tary industry review programs similar to those of the cosmetic industry.... Voluntary reporting programs
such as those found in the cosmetic industry are eective because industries prefer working with, rather than
against, the government."132 It should be noted, however, that the author of this suggestion recognized that
127Id. at IV-5.
128Bass & Young, supra note 14, at 58.
129Kaczka, supra note 4, at 491-492.
130O'Reilly, supra note 71,at 25.
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132Lauren J. Sloane, \Herbal Garden of Good and Evil: The Ongoing struggles of Dietary Supplement Regulation, 51 Admin. L.
Rev. 323, 340 (Winter, 1999).
42cosmetics are a low-risk product, so the applicability of a similar regulatory scheme is questionable.
Others critics are concerned about inadequate and misleading labels have said that \[o]ne option to remedy
this dilemma might be to utilize and insert or extended pull-out label that provides more complete informa-
tion for the consumer to use in making an educated decision."133
Still another commentator suggests an altogether dierent test than has been established by the nal rule:
\The key concept determining whether a claims is permitted under x 403(r)(6) is not whether the claim is
somehow related to one disease or another, but whether the claim when viewed in its entirety, is reasonably
related to the promotion of overall good health and well-being."134
Another suggestion would place further limits on dietary supplement manufacturers:
Supplement manufacturers should have a legally enforceable armative obligation to do
the testing needed to establish that supplements are safe. If they do not do safety testing, the
manufacturer should put a warning on the label that the safety of the supplement has not been
substantiated. Such a measurement would not require pre-market approval by FDA.135
Such a suggesting tracks very closely with the court's decision in Pearson v. Shalala, which can be expected
to bear directly on any future litigation involving the nal rule, as discussed below.
Pearson. Shalala
Although the courts have not addressed the viability of the FDA's new rule, one might expect the courts to
apply a similar reasoning to the new rule that the Court of Appeals for the District of Columbia did in Pearson
133Carl Germano, \Structure/Function Claims { Do they Truly Benet the Consumer? Despite the Legislative Strides made by
DSHEA, the Battle Goes On. http://www.solgar.com/nutrient library/opinion/structure function.html.
134Harrison, supra at note 13.
43v. Shalala, 164 F.3d 650, 334 U.S.App.D.C. 71 (1999) (despite the FDA's attempt to distinguish the case, as
noted earlier). The case involved an objection, on constitutional grounds, to the FDA's regulation under the
NLEA of dietary supplement labeling because it did not consider allowing the inclusion of disclaimers which
indicated the lack of both supporting studies and FDA approval but disallowed those claims altogether. Prior
to the Court of Appeal's decision in Pearson, \for health claims to be used, there need[ed] to be sucient
scientic agreement among qualied experts that the claim [were] factual and truthful."136 In Pearson, the
FDA had rejected claims which did not meet its signicant scientic agreement standard and rejected the
suggested disclaimer. The appellants objected to the regulation in 21 C.F.R.x 101.14 on First Amendment
grounds and claimed that the FDA was required under the Administrative Procedure Act to articulate its
\signicant scientic agreement" standard. The appellants further stated that even if the standard was
spelled out, then should be allowed to make non-conforming health claims if they are accompanied with a
disclaimer.
The Court of Appeals employed the Central Hudson Gas & Elec. Corp. v. Public Service Commission
of New York, 447 U.S. 557, 10 S.Ct. 2343, test, which considers three prongs: \First we ask whether
the asserted government interest is substantial.... [Second,] `whether the regulation directly advances the
governmental interest asserted.'... [Third,] whether the t between the government's ends and the meaning
chosen to accomplish those ends `is not necessary perfect, but reasonable."'137 The court quickly identied
the rst prong as satised because the FDA has a signicant interest in protecting the public interest by
\ensuring the accuracy of commercial information in the marketplace."138
However, the court cites diculties with the nal two prongs of the test. The court views the FDA's
justication for the regulation as dubious, seeing it as rather paternalistic.139 The court recognizes that the
136Paula Kurtzweil, \Staking a Claim to Good Health: Health Claims on Foods." FDA Consumer, p.16-18 (Nov./Dec. 1998).
137Pearson v. Shalala, 164, F.3d 650, 656, 334 U.S.App.D.C. 71, 76-77 (citing Central Hudson 447 U.S. 557, 100 S.Ct.
2343).
138Id. at 76.
139Id.
44second prong may, however, have been satised under a consumer fraud claim (although not applicable in
the specic products involved). But, it is this consumer fraud claim which created a worry about satisfying
the third prong of the Central Hudson test.140 The FDA claimed that \it is never obliged to utilize the
disclaimer approach because the commercial speech doctrine does not embody a preference for disclosure
over outright suppression."141 The court responds that \'the preferred remedy is more disclosure, rather
than less"'142 under the First Amendment The court atly rejects \the government's position that there is
no general First Amendment preference for disclosure over suppression."143
The court notes that its decision as to the third prong does not hold that inadequate claims should, therefor
be remedied by disclaimers and does not speak to the validity of the regulation in question. The court nds
that the FDA's interest could be satised by allowing for disclaimers.144 It notes that the FDA \must still
meet its burden of justifying a restriction on speech."145 The court only seems to support an outright ban
when the evidence supporting a claim is irresolute.146
Beyond the Central Hudson test, the court considered the appellant's \claim that the agency is obliged to
give some content to the phrase `signicant scientic agreement."'147 The appellants make this claim under
both the First and Fifth Amendments. The court agrees that both the APA claim and the Fifth Amendment
claim are valid. The court ultimately decides the unarticulated standard issue under the APA:
140Id at 77-78.
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45[T]he APA requires the agency to explain why it rejects their proposed health claims { to do so
adequately necessarily implies giving some denitional content to the phrase `signicant scientic
agreement'. We think this proposition is squarely rooted in the prohibition under the APA that an
agency not engage in arbitrary and capricious action.148
The court concludes that \it must be possible for the regulated class to perceive the principles which are
guiding agency action."149 The court requires, on remand, that the FDA provide an explanation and
standards for meeting its \signicant scientic agreement" standard.
It is hardly a stretch to recognize that the court's decision in Pearson has far-reaching implications for
the FDA's regulatory process: \[T]his proposed reg, contradicts in its breadth some of the recent rst
amendment decisions from the D.C. Circuit. Including the Washington Legal Foundation [a plainti] of
Pearson v. Shalala."150
A participant in the Committee on Government Reform hearing on March 25, 1999 summarized the holding
of Pearson in the following manner:
A recent case in the U.S. Court of Appeals for the DC Circuit addressed the health claims issues.
In this case, it was found that the FDA violated the rst amendment by refusing to use disclaimers
and authorize health claims. The FDA also violated the rst amendment by prohibiting specic
health claims. Additionally, the Court ruled that the FDA violated the Administrative Procedure
Act by refusing to dene its health claims review standard for dietary supplements.151
Another Representative described the FDA's action in the following fashion:
... [T[he FDA has ruled that it is illegal for companies who market psyllium to speak about the
benets of this nutrient. Illegal to speak. The FDA took it upon itself to alter this little bit of the
Constitution without bothering to check with the rest of us on it.152
Despite the Court's holding in Pearson, there exists the possibility the courts will follow the holding in
Henley v. FDA, 873 F.Supp. 776 (DATES?] which that the FDA's decision to deny a citizen's petition for
additional warning labeling on products containing estrogen was not arbitrary, capricious or an abuse of
149Id. at 82.
150Id. at 84.
46discretion. The court found a rational basis for the denial and said that the decision was within the agency's
authority.
In response to the court's decision in Pearson, the FDA ultimately published a nal rule under the NLEA
entitled \Food Labeling: Statement of Identity, Nutrition Labeling of Dietary Supplements: Compliance
Policy Guide, Revocation \ 21 C.F.R. x 101.36 (1998), 62 Fed.Reg. 49,826 (Sept. 23, 1997). This rule was
intended to respond to the Pearson holding by providing more complete information on the labels of dietary
supplements. The FDA may ultimately be forced to similar actions under the DSHEA.
Conclusion
With the implementation of its nal rule concerning structure/function statements on dietary supplement
labels, the FDA has attempted to implement the Dietary Supplement Health and Education Act. Whether
it has succeeded remains to be seen. Although the FDA attempts to clarify the DSHEA with its recent
promulgation of rules, the questions which remain to be addressed are varied and signicant. Will the courts
continue in their current direction in limiting restrictions on the marketing of dietary supplements? See
Pharmanex, Inc. v. Shalala, 35 F.Supp.2d 1341 (D.Utah 1999). Will the FDA provide further guidance
to manufacturers (and ultimately consumers) regarding acceptable structure/function claims? For surely,
confusion exists as to acceptable claims as can be seen in the following statement in a recent news report:
\fA product] can bear label advertising the product's ability to lower cholesterol."153 This would certainly
not be an acceptable structure/function, but the consumer would not know of the inaccuracy of this report.
Will scarce funding thwart the FDA's enforcement eorts in regulation the labeling of dietary supplement?154
153Daryn Eller, \Herbal Food Additives: Making Sense of the Claims," http"//www.cnn.com/HEALTH/9903/23/dietary.supplements/hsindex.html,
9/20/00.
154U.S. Says Lack of Funding Hampers Supplement Law. http:www.cnn.com/2001/HEALTH/diet.tness/03/21/health.supplements.reut/index.htm.
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47Regardless of the answers to these pressing questions, it is clear that the increasing popularity of dietary
supplements requires at least some level of regulation. Whether this regulation will be of the strict sort
supported by the FDA or a lesser standard as intended by Congress remains to be seen.
48